TickerFacts.

Eupraxia Pharmaceuticals Inc. (EPRX): Net Income

Annual figures by period end, from SEC filings.

-$38.58M
Year ended 2025-12-31
2022-12-31: -$18.49M2023-12-31: -$28.22M2024-12-31: -$25.50M2025-12-31: -$38.58M-$38.58M
2022-12-31 Net Income (USD) 2025-12-31
Period endedNet IncomeChange YoYSource filing
2025-12-31-$38.58Mn/m2026-03-13, From 2025-01-01
2024-12-31-$25.50Mn/m2026-03-13, From 2024-01-01
2023-12-31-$28.22Mn/m2025-03-20, From 2023-01-01
2022-12-31-$18.49Mn/a2024-04-01, From 2022-01-01

Net Income at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedNet IncomeChange YoY
Eupraxia Pharmaceuticals Inc. (EPRX)2025-12-31-$38.58Mn/m
Abbott Laboratories (ABT)2025-12-31$6.52B-51.3%
Bristol Myers Squibb Co (BMY)2025-12-31$7.05Bn/m
TherapeuticsMD, Inc. (TXMD)2025-12-31-$569.0Kn/m
Eli Lilly & Co (LLY)2025-12-31$20.64B+94.9%
Pfizer Inc (PFE)2025-12-31$7.77B-3.2%
Johnson & Johnson (JNJ)2025-12-28$26.80B+90.6%
Nature's Sunshine Products Inc (NATR)2025-12-31$20.45M+159.1%
Merck & Co., Inc. (MRK)2025-12-31$18.25B+6.6%

Compare EPRX, ABT, BMY, TXMD side by side · Screen every company in Pharmaceutical Preparations ↗